<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberculosis and the eye</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberculosis and the eye</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tuberculosis and the eye</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sivakumar R Rathinam, FAMS, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew F Gardiner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5509035"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberculosis (TB) is an infectious disease caused by <em>Mycobacterium tuberculosis</em> that can affect many organs, including the eye [<a href="#rid1">1-4</a>]. Ocular TB can involve any part of the eye and can occur with or without evidence of systemic TB. It generally develops following hematogenous spread from a primary focus but, in rare cases, it can also occur as a primary infection following an epithelial injury. Establishing the diagnosis of TB in an extrapulmonary focus is a clinical challenge. </p><p>Issues related to ocular TB will be reviewed here. Issues related to other aspects of TB, including ocular toxicities of TB medications, are discussed in detail separately. (See related topics.)</p><p class="headingAnchor" id="H5509042"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>TB is an airborne communicable disease of major public health significance in many countries. General issues related to epidemiology of TB are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8018.html" rel="external">"Epidemiology of tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/8029.html" rel="external">"Epidemiology and pathology of miliary and extrapulmonary tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/8027.html" rel="external">"Epidemiology and molecular mechanisms of drug-resistant tuberculosis"</a>.)</p><p>Most TB disease involves the pulmonary system. Ocular TB usually represents extrapulmonary dissemination of infection. The incidence of ocular TB is uncertain due to difficulties in ocular sampling for microbiology and lack of definitive diagnostic criteria [<a href="#rid5">5,6</a>]. Prior to the era of HIV/AIDS, two prospective studies of patients with TB admitted to a sanatorium noted ocular disease incidence of 1 to 2 percent [<a href="#rid7">7,8</a>]. </p><p>Among patients with HIV infection:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study including 103 patients with pulmonary tuberculosis, ocular inflammation was observed in 7 cases (6.8 percent prevalence: 95% CI 2.78 to 13.5) [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study including 98 patients with HIV infection, tuberculosis retinochoroiditis was seen in 7 percent [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study including 85 patients with HIV and TB, ocular tuberculosis was observed in 11 patients (12.9 percent) [<a href="#rid11">11</a>].</p><p></p><p>These studies suggest that routine ocular examination is warranted in patients with suspected or proven TB, especially if eye symptoms are present. </p><p class="headingAnchor" id="H5509049"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>TB of the eye may involve internal or the external structures. Three manifestations of ocular TB have been described based on mode of transmission of bacilli to the ocular tissues.</p><p class="bulletIndent1"><span class="glyph">●</span>Most commonly, ocular TB develops as a result of hematogenous spread of <em>M. tuberculosis</em> from pulmonary or extrapulmonary sites. The clinical manifestations consist of intraocular findings (<a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">figure 1</a>); these include choroiditis, chorioretinitis, serpiginous choroiditis choroidal granuloma, optic neuritis, optic disc granuloma, subretinal abscess, orbital cellulitis, scleritis, necrotizing scleritis, posterior scleritis, sclerokeratouveitis, (<a class="graphic graphic_picture graphicRef87839" href="/z/d/graphic/87839.html" rel="external">picture 1</a>), interstitial keratitis, and anterior chamber granuloma (<a class="graphic graphic_picture graphicRef87840" href="/z/d/graphic/87840.html" rel="external">picture 2</a>) [<a href="#rid1">1-4,12-15</a>]. More recently in many patients primary intraocular tuberculosis without evidence of pulmonary or other extra pulmonary tuberculosis have been reported [<a href="#rid13">13</a>]. In these patients probably primary location of infection is mild to be symptomatic or to be traced. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less commonly, ocular TB can occur as a result of direct ocular infection from an exogenous source. In such cases, infection may involve the ocular adnexa, lacrimal gland, conjunctiva, sclera, or cornea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In rare cases, eye involvement can occur as a result of a hypersensitivity reaction to a distant focus of infection. Manifestations may include episcleritis, phlyctenular keratoconjunctivitis, nodular inflammation of the conjunctiva, episclera or sclera resulting from hypersensitivity reaction to a foreign antigen such as tuberculin protein (<a class="graphic graphic_picture graphicRef131988" href="/z/d/graphic/131988.html" rel="external">picture 3</a>). Occlusive retinal vasculitis is similar hypersensitivity reaction and often named as Eales' disease. (See <a class="local">'Intraocular TB'</a> below and  <a class="medical medical_review" href="/z/d/html/8220.html" rel="external">"Eales disease"</a>.)</p><p></p><p class="headingAnchor" id="H5509084"><span class="h2">Intraocular TB</span><span class="headingEndMark"> — </span>Intraocular TB most commonly affects the uveal tract, which includes the iris and ciliary body (anteriorly) and the choroid (posteriorly). The choroid is a vascular layer located between the sclera and the retina; it forms the middle or vascular coat of the eye. Anatomically, tubercular uveitis may present as anterior, intermediate, posterior, or pan uveitis [<a href="#rid1">1-4,12-15</a>].</p><p>The diagnosis of intraocular TB can be challenging as the clinical manifestations are variable. Definitive diagnosis of TB is established by isolation of bacilli from the ocular tissues, which is often difficult to achieve. Therefore, a diagnosis of TB is frequently presumed in the presence of suggestive ocular findings (such as choroidal granuloma, broad-based posterior synechiae, retinal vasculitis with or without choroiditis, or serpiginous-like choroiditis) in combination with systemic findings consistent with TB (such as positive acid-fast bacilli [AFB] smear and culture, consistent radiographic findings, or a positive interferon-gamma release assay [IGRA] or <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> [TST] in individuals with no systemic symptoms). Molecular diagnostic testing is also a useful tool. Clinical response to antituberculous therapy further supports a presumed diagnosis of ocular TB. (See <a class="local">'Treatment'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Uveitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anterior – Tubercular anterior uveitis is characterized by granulomatous keratic precipitates (<a class="graphic graphic_picture graphicRef87841" href="/z/d/graphic/87841.html" rel="external">picture 4</a>), iris granulomas (<a class="graphic graphic_picture graphicRef88548" href="/z/d/graphic/88548.html" rel="external">picture 5</a>), and broad-based posterior synechiae; occasionally, hypopyon may be observed (<a class="graphic graphic_picture graphicRef87840" href="/z/d/graphic/87840.html" rel="external">picture 2</a>). Cataract is a common complication. Unlike sarcoid uveitis, open-angle glaucoma is not common in tuberculous uveitis, although annular synechiae and iris bombe can cause secondary angle closure glaucoma. Untreated chronic anterior uveitis may result in phthisis bulbi (an atrophic, scarred globe) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Posterior – Choroidal TB is the most common form of posterior uveitis. It occurs most commonly in the presence of systemic TB and in rare cases, it is the sole manifesting presentation of TB or the initial manifestation of systemic disease. Choroidal TB may be unilateral or bilateral. Three funduscopic patterns have been described (<a class="graphic graphic_picture graphicRef87842" href="/z/d/graphic/87842.html" rel="external">picture 6</a>): solitary tubercle, miliary choroidal tubercles, or tuberculoma (a single large lesion that may mimic tumor and can lead to serious retinal detachment) (<a class="graphic graphic_picture graphicRef62218" href="/z/d/graphic/62218.html" rel="external">picture 7</a>) [<a href="#rid4">4,10-15</a>].</p><p></p><p class="bulletIndent2">Tubercles appear as ill-defined, yellowish-white elevated nodules. They vary in size from a pinpoint to several disc diameters in size. The lesions can coalesce into larger elevated choroidal nodules. Focal choroidal granuloma or diffuse subretinal abscess may be observed as elevated lesions in the fundus [<a href="#rid12">12</a>]. Ultrasonography can demonstrate focal retinochoroidal thickening. After antituberculous treatment, the lesion becomes pigmented. In some cases, choroidal neovascular membrane develops after complete healing, which may be associated with vision loss. Such patients are further treated with intravitreal injection of antivascular endothelial growth factor (<a class="graphic graphic_picture graphicRef87842" href="/z/d/graphic/87842.html" rel="external">picture 6</a>) [<a href="#rid4">4</a>]. As the lesions age, the borders become more distinct and the rim becomes pigmented (<a class="graphic graphic_picture graphicRef62218" href="/z/d/graphic/62218.html" rel="external">picture 7</a>). Multifocal chorioretinitis with pigmented scars often indicates a tubercular etiology (<a class="graphic graphic_picture graphicRef87843" href="/z/d/graphic/87843.html" rel="external">picture 8</a>) [<a href="#rid4">4,15</a>].</p><p></p><p class="bulletIndent2">Patients with choroidal tubercle(s) near or at the macula present with diminished visual acuity. Patients with choroidal tubercle(s) at sites not adjacent to the macula are asymptomatic and lesions may be identified incidentally on screening ocular examination.</p><p></p><p class="bulletIndent2">Serpiginous-like choroiditis (SLC) of presumed tubercular etiology closely mimics serpiginous choroidopathy (SC) (<a class="graphic graphic_picture graphicRef87843" href="/z/d/graphic/87843.html" rel="external">picture 8</a>). Patients with SLC are more likely to develop multifocal scattered highly pigmented lesions with vitreous cells, in contrast with classic SC, which is characteristically less pigmented [<a href="#rid16">16</a>]. It is important to exclude TB as the cause of serpiginous-like choroidopathy. Optic disc granuloma may be seen, and it can mimic a sarcoid granuloma (<a class="graphic graphic_picture graphicRef87842" href="/z/d/graphic/87842.html" rel="external">picture 6</a>) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immune recovery – Immune recovery uveitis (IRU) can occur among patients with HIV and TB in the setting of immune reconstitution due to antiretroviral therapy. IRU has been described among patients with HIV and concurrent TB, cytomegalovirus retinitis, and varicella-zoster ocular infection. Severe IRU resulting in globe rupture has been reported in an HIV patient with coexisting tubercular uveitis (<a class="graphic graphic_picture graphicRef88548" href="/z/d/graphic/88548.html" rel="external">picture 5</a>) [<a href="#rid17">17</a>]. Additional issues related to immune reconstitution inflammatory syndrome are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome", section on 'Tuberculosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retinal TB – Tuberculous involvement of the retina alone is uncommon. More frequently, the retina is involved in the setting of choroidal TB as retinochoroiditis. The diagnosis of retinal TB is usually presumptive based upon clinical evaluation of the eye and evaluation for evidence of systemic TB disease and/or tuberculin (or IGRA) reactivity; biopsy of the retina is generally not possible. Exudative retinal hemorrhagic periphlebitis in a patient with uveitis is highly suggestive of tubercular etiology. Similarly, healed periphlebitis and perivascular healed chorioretinal scars indicate a tubercular cause (<a class="graphic graphic_picture graphicRef87840" href="/z/d/graphic/87840.html" rel="external">picture 2</a>) [<a href="#rid1">1,2,4</a>]. Fundus <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography demonstrates retinal vessel wall staining and vascular leakage. Other signs include subvascular lesions, focal vascular tortuousities, and occlusive vasculitis (<a class="graphic graphic_picture graphicRef131989" href="/z/d/graphic/131989.html" rel="external">picture 9</a>) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Eales' disease is a retinal perivasculitis affecting the peripheral retina of otherwise healthy adults. It is unclear whether this condition occurs as a result of TB disease or whether it reflects an independent retinal hypersensitivity reaction. In one study of 50 patients with Eales' disease, <em>M. tuberculosis</em> DNA was demonstrated by polymerase chain reaction in four patients (8 percent) [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/8220.html" rel="external">"Eales disease"</a>.)</p><p></p><p class="headingAnchor" id="H5509155"><span class="h2">TB of the external eye</span><span class="headingEndMark"> — </span>External eye structures can be involved in ocular TB including orbit, eyelid, lacrimal gland, conjunctiva, and sclera.</p><p class="bulletIndent1"><span class="glyph">●</span>Orbit – Involvement of the orbit occurs most commonly in children, although rare cases have been reported in adults [<a href="#rid19">19</a>]. Frequent findings include a draining sinus tract and/or radiographic evidence of bony destruction [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eyelid – TB of the eyelid (tarsus) presents as an eyelid abscess or a chalazion-like mass. Occasionally, spontaneous drainage of the abscess forms a draining sinus tract [<a href="#rid22">22</a>]. An apparent chalazion (granuloma of an internal sebaceous gland leading to a localized swelling) that recurs despite surgical excision should prompt consideration of TB.</p><p></p><p class="bulletIndent1">TB of the eyelid can also develop as an extension of cutaneous TB [<a href="#rid22">22,23</a>]. The skin disease consists of subepithelial nodules ("apple jelly nodules"), scaly plaques, or, rarely, erosive ulcers with destruction of facial features [<a href="#rid24">24</a>]. The eyelid is involved as an extension of infection from the surrounding skin. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lacrimal gland – TB of the lacrimal gland can present as symptomatic dacryoadenitis [<a href="#rid25">25</a>]; the presentation may be indistinguishable clinically from bacterial infection. Failure to respond to antibiotic treatment should prompt histopathological study of the gland.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctiva – Primary conjunctival tuberculosis is rare, however it is reported [<a href="#rid26">26</a>]. Tuberculous infection of the conjunctiva may present as an ulcer, subconjunctival nodule, pedunculated polyp, or tuberculoma (hard, nodular, nonulcerating mass) [<a href="#rid26">26</a>]. Diagnosis requires an excisional biopsy with histopathology and culture. The number of organisms is usually small, so acid-fast bacilli may not be observed. Phlyctenular keratoconjunctivitis (<a class="graphic graphic_picture graphicRef131988" href="/z/d/graphic/131988.html" rel="external">picture 3</a>) is rarely seen in patients with active TB. It appears to be associated with tuberculoprotein hypersensitivity but not with active ocular infection [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratoconjunctivitis – Tuberculous infection of the cornea presents with pain and photophobia. Examination of the cornea may demonstrate corneal erosion with stromal infiltration (<a class="graphic graphic_picture graphicRef87839" href="/z/d/graphic/87839.html" rel="external">picture 1</a>). When phlycten migrates over the cornea, it drags conjunctival vessels, and it is named as fascicular ulcer. Deep stromal keratitis is characteristic of tubercular infection of the cornea. The disease may be associated with anterior uveitis and/or conjunctivitis. Local lymph nodes may also be enlarged [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sclera – Tuberculous infection of the sclera (external or fibrous coat of the eye) results from hematogenous spread. The diagnosis can be difficult to establish and is primarily based upon evidence of scleral inflammation in a patient with active TB at another body site (<a class="graphic graphic_picture graphicRef76194" href="/z/d/graphic/76194.html" rel="external">picture 10</a>) [<a href="#rid28">28-31</a>].</p><p></p><p class="headingAnchor" id="H2150862219"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Granulomatous uveitis may also be seen in patients with herpes simplex or varicella-zoster infection, phacoantigenic uveitis, sarcoidosis, syphilis, leprosy, Vogt-Koyanagi-Harada disease, fungal lesions and sympathetic ophthalmia. Clinical manifestations of nontuberculous mycobacterial infections also simulate TB [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H5509229"><span class="h1">LABORATORY EVALUATION</span><span class="headingEndMark"> — </span>Isolation of <em>M. tuberculosis</em> by culture is the cornerstone for diagnosis of TB, although this is not always feasible [<a href="#rid28">28</a>]. Even if a specimen can be obtained, it is often too small for all procedures, such as Ziehl-Neelsen staining for light microscopy and/or inoculation in liquid and solid media. Isolation of <em>M. tuberculosis</em> by culture may take 1 to 10 weeks; however, if growth is obtained, species identification and drug susceptibility testing are possible. Tuberculin skin testing and interferon-gamma release assays for TB infection may support a presumed diagnosis of ocular TB if positive; however, the test result cannot be used to confirm the diagnosis. Conversely, a negative result for any of these tests does not rule out the disease [<a href="#rid28">28,32</a>].</p><p>Biopsy specimens may be obtained for histopathologic analysis either from the iris or by retinochoroidal biopsy. However, absence of acid-fast bacilli or of caseating necrosis in the biopsy specimen does not rule out ocular TB [<a href="#rid4">4,28</a>]. </p><p>Xpert MTB/RIF is a nucleic acid amplification (real-time PCR) assay rapidly detects the presence of both <em>M. tuberculosis</em> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> resistance by PCR and it is widely used in ocular fluids [<a href="#rid33">33-35</a>]. WHO recommended Xpert MTB/RIF Ultra, based on its increased sensitivity compared to Xpert, to improve the diagnosis of paucibacillary forms of TB disease such as extrapulmonary TB [<a href="#rid36">36</a>]. Multiplex PCR can be used as a marker for detecting viable <em>M. tuberculosis </em>in patients with suspected intraocular TB [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>When such techniques are not possible and while awaiting culture information, the diagnosis of TB is presumptive based on ocular examination and evidence of systemic infection. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>Multimodal imaging has greatly enhanced the characterization of ocular TB lesions. Fundus autofluorescence, optical coherence tomography (OCT), and OCT angiography have all been used for the identification of disease pattern and response to treatment in serpiginous-like choroiditis [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H5509243"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The approach to treatment of ocular TB is generally the same as that for pulmonary TB. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults"</a>.)</p><p>In general, for circumstances in which ocular TB is considered strongly as a clinical diagnosis, treatment should not be delayed until culture data become available [<a href="#rid38">38</a>]. Rifampicin-resistant tubercular choroidal granuloma has been reported to be treated successfully with second line antitubercular drugs. Early recognition of drug-resistant TB and appropriate treatment improves prognosis. <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">Ethambutol</a> and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> appear to have similar ocular adverse reaction resulting in optic neuropathy, and careful follow-up is needed for early recognition and intervention [<a href="#rid39">39</a>].</p><p>The response to therapy can usually be assessed by the clinical examination and resolution of inflammation. In the setting of choroidal TB, lesions can resolve completely with treatment. Paramacular and optic nerve head TB is managed with antituberculous therapy together with systemic corticosteroids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg orally once daily) followed by a taper depending on the clinical response [<a href="#rid40">40</a>]. Development of neovascularization warrants photocoagulation of the retina (<a class="graphic graphic_picture graphicRef131989" href="/z/d/graphic/131989.html" rel="external">picture 9</a>).</p><p>Some favor administration of antituberculous treatment for two to four weeks without steroids, followed by assessment for clinical improvement and subsequent determination regarding addition of steroids. However, for cases in which a lesion is present near the macula or optic disc, administration of concomitant steroids is mandatory to save these delicate structures from rebound inflammation that may occur with antituberculous therapy alone. In such situations, absence of recurrence following completion of the treatment supports a clinical diagnosis [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H3517945859"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">"Society guideline links: Diagnosis and treatment of tuberculosis"</a>.)</p><p class="headingAnchor" id="H5509250"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular tuberculosis (TB) can involve any part of the eye and can occur with or without evidence of pulmonary or extrapulmonary TB. Ocular TB usually arises after hematogenous spread from a primary focus. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three forms of ocular TB have been described based on mode of transmission of bacilli to the ocular tissues. Most commonly, ocular TB develops as a result of hematogenous spread of <em>Mycobacterium tuberculosis</em> from pulmonary or extrapulmonary sites. Less commonly, ocular TB can occur as a result of direct ocular infection from an exogenous source. In rare cases, eye involvement can occur as a result of a hypersensitivity reaction to a distant focus of infection. (See <a class="local">'Clinical manifestations and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common manifestation of intraocular TB is choroidal tubercles. External eye structures that can be involved in ocular TB include the orbit, eyelid, lacrimal gland, conjunctiva, and sclera. TB of these structures can occur as a result of hematogenous spread or via extension of adjacent infection involving the skin or the sinuses. (See <a class="local">'Clinical manifestations and diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A diagnosis of ocular TB is most often a clinical diagnosis, with ocular findings supported by a consistent risk history, evidence for TB elsewhere (such as the lungs), and/or a positive test for TB infection such as the <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) or an interferon-gamma release assay (IGRA), since culture of eye tissue or fluid is often not possible. A positive TST or IGRA may support a clinical diagnosis of TB, but it does not establish the diagnosis. Conversely, a negative test result does not rule out active TB. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy specimens may be obtained for histopathologic analysis either from the iris or by retinochoroidal biopsy. Absence of acid-fast bacilli or of caseating necrosis in the biopsy specimen does not rule out ocular TB; in such circumstances, nucleic acid amplification may be useful. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to treatment of ocular TB is generally the same as that for pulmonary TB. In general, for circumstances in which TB is considered strongly as a clinical diagnosis, treatment should not be delayed until culture data become available. The response to therapy can be assessed by the clinical examination and resolution of objective sites of clinical involvement. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H22642386"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Michele Trucksis, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kon OM, Beare N, Connell D, et al. BTS clinical statement for the diagnosis and management of ocular tuberculosis. BMJ Open Respir Res 2022; 9.</a></li><li class="breakAll">Neuhouser AJ, Sallam A.. Ocular Tuberculosis, StatPearls Publishing, Treasure Island (FL) 2023.</li><li><a class="nounderline abstract_t">Basu S, Elkington P, Rao NA. Pathogenesis of ocular tuberculosis: New observations and future directions. Tuberculosis (Edinb) 2020; 124:101961.</a></li><li class="breakAll">Albert DM, Miller J, Azard D, et al. Ocular tuberculosis. In: Albert and Jakobiec's Principles and Practice of Ophthalmology, 4th ed, Springer Nature, Switzerland AG 2022. p.4209-4226.</li><li><a class="nounderline abstract_t">Helm CJ, Holland GN. Ocular tuberculosis. Surv Ophthalmol 1993; 38:229.</a></li><li><a class="nounderline abstract_t">Yeh S, Sen HN, Colyer M, et al. Update on ocular tuberculosis. Curr Opin Ophthalmol 2012; 23:551.</a></li><li><a class="nounderline abstract_t">Donahue HC. Ophthalmologic experience in a tuberculosis sanatorium. Am J Ophthalmol 1967; 64:742.</a></li><li><a class="nounderline abstract_t">Goldenburg M, Fabricant ND. The eye in the tuberculous patient. Trans Sect Ophthalmol Am Med Assn 1930; 135:8.</a></li><li><a class="nounderline abstract_t">Lara LP, Ocampo V Jr. Prevalence of presumed ocular tuberculosis among pulmonary tuberculosis patients in a tertiary hospital in the Philippines. J Ophthalmic Inflamm Infect 2013; 3:1.</a></li><li><a class="nounderline abstract_t">Saadouli D, Ammari L, Ben Mansour K, et al. Ocular manifestations of people living with HIV in Tunisia. South Afr J HIV Med 2021; 22:1193.</a></li><li><a class="nounderline abstract_t">Jain S, Bajgai P, Kaur S, et al. Ocular Tuberculosis in Human Immunodeficiency Virus and Systemic Tuberculosis Co-infected Patients. Ocul Immunol Inflamm 2021; 29:1002.</a></li><li><a class="nounderline abstract_t">Kaya M, Ömeroglu Şimşek G, Ucan ES, et al. Types of Fundus Involvement in Intraocular Tuberculosis. Turk Thorac J 2022; 23:322.</a></li><li><a class="nounderline abstract_t">Nandu NS, Bavanasi A, Wajahat R. Ocular Tuberculosis Without a Lung Primary. Cureus 2020; 12:e7920.</a></li><li><a class="nounderline abstract_t">Testi I, Agrawal R, Mehta S, et al. Ocular tuberculosis: Where are we today? Indian J Ophthalmol 2020; 68:1808.</a></li><li><a class="nounderline abstract_t">Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Tubercular Uveitis. Am J Ophthalmol 2021; 228:142.</a></li><li><a class="nounderline abstract_t">Bansal R, Gupta V. Tubercular serpiginous choroiditis. J Ophthalmic Inflamm Infect 2022; 12:37.</a></li><li><a class="nounderline abstract_t">Rathinam SR, Lalitha P. Paradoxical worsening of ocular tuberculosis in HIV patients after antiretroviral therapy. Eye (Lond) 2007; 21:667.</a></li><li><a class="nounderline abstract_t">Gupta P, Biswas J. Further evidence of the association of latent Mycobacterium tuberculosis in Eales' disease. Int Ophthalmol 2021; 41:901.</a></li><li><a class="nounderline abstract_t">Sohail M, Maniar A, Winn BJ, et al. Orbital tuberculosis: a case report and update on the role of imaging in treatment. Orbit 2022; :1.</a></li><li><a class="nounderline abstract_t">Bhattacharya S, K Raina U, K Gupta S, et al. Tubercular Osteomyelitis of the Orbit Presenting as Periorbital Cellulitis. J Ophthalmic Vis Res 2022; 17:146.</a></li><li><a class="nounderline abstract_t">Küchlin S, Glegola M, Schulz T, Auw-Hädrich C. Histological Diagnosis of Ocular and Periocular Tuberculosis 1945 - 2020. Klin Monbl Augenheilkd 2022; 239:876.</a></li><li><a class="nounderline abstract_t">Albab N, Hakam J, Belghmaidi S, et al. A rare case of primary tuberculosis of the eyelid. J Fr Ophtalmol 2020; 43:e287.</a></li><li><a class="nounderline abstract_t">Mohan K, Prasad P, Banerjee AK, Dhir SP. Tubercular tarsitis. Indian J Ophthalmol 1985; 33:115.</a></li><li><a class="nounderline abstract_t">Dinning WJ, Marston S. Cutaneous and ocular tuberculosis: a review. J R Soc Med 1985; 78:576.</a></li><li><a class="nounderline abstract_t">Madhukar K, Bhide M, Prasad CE, Venkatramayya . Tuberculosis of the lacrimal gland. J Trop Med Hyg 1991; 94:150.</a></li><li><a class="nounderline abstract_t">Liang ZQ, Zhang Q, Zhao MW, et al. Primary conjunctival tuberculosis in two middle-aged women. Int J Ophthalmol 2020; 13:180.</a></li><li><a class="nounderline abstract_t">Wiriyachai T, Boonsathorn S, Apiwattanakul N, Assawawiroonhakarn S. A rare case of primary sinonasal tuberculosis presented with phlyctenular keratoconjunctivitis in a pediatric patient: A case report and literature review. Medicine (Baltimore) 2021; 100:e24787.</a></li><li><a class="nounderline abstract_t">Rathinam SR. Tubercular uveitis and scleritis. Focal Points (AAO) 2017; 10:1.</a></li><li><a class="nounderline abstract_t">Aldebasi TM, Alasiri AA, Alnahdi MA, Alfarhan A. Tubercular Episcleritis: A Review of Literature. Middle East Afr J Ophthalmol 2022; 29:51.</a></li><li><a class="nounderline abstract_t">Agarwal M, Patnaik G, Agarwal S, et al. Tuberculous Scleritis and Multidrug Resistance. Ocul Immunol Inflamm 2022; 30:915.</a></li><li><a class="nounderline abstract_t">Agarwal AM, Dutta Majumder P. Tubercular posterior scleritis: A case report and review of literature. Indian J Ophthalmol 2019; 67:1362.</a></li><li><a class="nounderline abstract_t">Agrawal T, Multani P, Shetty SB, Sen A. Bilateral Ocular Tuberculosis in a Child with Negative Tuberculin Skin Test (TST): A Diagnostic Dilemma. Ocul Immunol Inflamm 2022; 30:1199.</a></li><li><a class="nounderline abstract_t">Sharma K, Sharma M, Ayyadurai N, et al. Comparative Evaluation of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF for Detecting Tuberculosis and Identifying Rifampicin Resistance in Pars Plana Vitrectomy Samples of Patients with Ocular Tuberculosis. Ocul Immunol Inflamm 2023; 31:914.</a></li><li><a class="nounderline abstract_t">Sharma K, Gupta A, Sharma M, et al. Detection of viable Mycobacterium tuberculosis in ocular fluids using mRNA-based multiplex polymerase chain reaction. Indian J Med Microbiol 2022; 40:254.</a></li><li><a class="nounderline abstract_t">Sharma K, Sharma M, Ayyadurai N, et al. Evaluating Truenat Assay for the Diagnosis of Ocular Tuberculosis and Detection of Drug Resistance. Ocul Immunol Inflamm 2023; :1.</a></li><li class="breakAll">Next-generation Xpert® MTB/RIF Ultra assay recommended by WHO. TB Online. Available at: https://www.tbonline.info/posts/2017/3/27/next-generation-xpert-mtbrif-ultra-assay-recommend/. (Accessed on May 10, 2023).</li><li><a class="nounderline abstract_t">Madaan S, Magesan K, Verma A, Biswas J. Clinical profile, multimodal imaging, and treatment response in macular serpiginous choroiditis. Indian J Ophthalmol 2022; 70:435.</a></li><li><a class="nounderline abstract_t">Agrawal R, Testi I, Bodaghi B, et al. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis. Ophthalmology 2021; 128:277.</a></li><li><a class="nounderline abstract_t">Zhang P, Li W, Liu M, et al. Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China. Infect Drug Resist 2022; 15:2617.</a></li><li><a class="nounderline abstract_t">Basu S, Nayak S, Padhi TR, Das T. Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting. Eye (Lond) 2013; 27:657.</a></li></ol></div><div id="topicVersionRevision">Topic 7999 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35379660" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : BTS clinical statement for the diagnosis and management of ocular tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35379660" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : BTS clinical statement for the diagnosis and management of ocular tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010848" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pathogenesis of ocular tuberculosis: New observations and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010848" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pathogenesis of ocular tuberculosis: New observations and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8310395" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ocular tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23047173" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Update on ocular tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6061532" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ophthalmologic experience in a tuberculosis sanatorium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The eye in the tuberculous patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514121" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of presumed ocular tuberculosis among pulmonary tuberculosis patients in a tertiary hospital in the Philippines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33824735" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ocular manifestations of people living with HIV in Tunisia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32083986" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ocular Tuberculosis in Human Immunodeficiency Virus and Systemic Tuberculosis Co-infected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35943072" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Types of Fundus Involvement in Intraocular Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32494534" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ocular Tuberculosis Without a Lung Primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32823397" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ocular tuberculosis: Where are we today?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33845014" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Classification Criteria for Tubercular Uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36352169" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tubercular serpiginous choroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17139273" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Paradoxical worsening of ocular tuberculosis in HIV patients after antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200391" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Further evidence of the association of latent Mycobacterium tuberculosis in Eales' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36154445" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Orbital tuberculosis: a case report and update on the role of imaging in treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35194506" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tubercular Osteomyelitis of the Orbit Presenting as Periorbital Cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35858599" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Histological Diagnosis of Ocular and Periocular Tuberculosis 1945 - 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571527" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A rare case of primary tuberculosis of the eyelid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3833735" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tubercular tarsitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3892000" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cutaneous and ocular tuberculosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2051518" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tuberculosis of the lacrimal gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31956587" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Primary conjunctival tuberculosis in two middle-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33607832" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A rare case of primary sinonasal tuberculosis presented with phlyctenular keratoconjunctivitis in a pediatric patient: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tubercular uveitis and scleritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36685347" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tubercular Episcleritis: A Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33416427" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tuberculous Scleritis and Multidrug Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31332144" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tubercular posterior scleritis: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33826463" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bilateral Ocular Tuberculosis in a Child with Negative Tuberculin Skin Test (TST): A Diagnostic Dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442853" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparative Evaluation of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF for Detecting Tuberculosis and Identifying Rifampicin Resistance in Pars Plana Vitrectomy Samples of Patients with Ocular Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35058073" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Detection of viable Mycobacterium tuberculosis in ocular fluids using mRNA-based multiplex polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36726220" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evaluating Truenat Assay for the Diagnosis of Ocular Tuberculosis and Detection of Drug Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36726220" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluating Truenat Assay for the Diagnosis of Ocular Tuberculosis and Detection of Drug Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35086211" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical profile, multimodal imaging, and treatment response in macular serpiginous choroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32603726" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35634579" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449506" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
